Quality Control Parameters of Crude Drugs

[1]Nasruddin Ansari, [2]Prof. Garima Indurkhya
[1]B. Pharm 8th Semester, Bansal College of Pharmacy, Bhopal (M.P.), India
[2]Associate Professor, Affiliated to: Rajiv Gandhi Proudyogiki Vishwavidyalaya (RGPV), Bhopal

Abstract*—Crude drugs derived from plant, animal, and mineral origins constitute the foundational raw materials of traditional medicine systems and occupy a pivotal position in contemporary phytopharmaceutical development. In contrast to chemically synthesized agents — which represent discrete, well-characterized molecular entities — crude drugs comprise intricate biochemical mixtures whose therapeutic properties arise from multi-constituent interactions. The chemical profile, and consequently the efficacy and safety profile, of any crude drug is subject to considerable variation arising from genetic diversity, cultivation geography, harvest timing, post-collection handling, and deliberate or inadvertent adulteration. Such variability renders systematic quality assurance both scientifically indispensable and commercially necessary. Approximately 80% of the global population depends on herbal remedies as the primary avenue of healthcare, underscoring the urgency of rigorous standardization frameworks. This review article systematically examines the multi-tiered quality control parameters applied to crude drugs, encompassing organoleptic and macroscopic characterization, microscopic histological profiling, physicochemical determinations (moisture content, ash values, extractive values, volatile oil content), preliminary and advanced chemical evaluation (chromatographic fingerprinting, spectroscopic methods), and biological safety testing (heavy metal quantification, pesticide residue analysis, mycotoxin screening, microbiological assessment). Special focus is accorded to two exemplary crude drugs — Neem (Azadirachta indica) and Turmeric (Curcuma longa) — as case studies demonstrating the practical application of these parameters. Emerging analytical innovations including DNA barcoding, metabolomics, chemometrics, and portable near-infrared spectroscopy are also discussed as future trajectories in herbal quality management.

***Index Terms*—Crude drugs; Pharmacognostic evaluation; Organoleptic analysis; Phytochemical screening; Chromatographic fingerprinting; Herbal standardization; WHO guidelines; Neem; Turmeric; Quality assurance**

I. INTRODUCTION

1.1 Defining Crude Drugs and Their Pharmaceutical Relevance

A crude drug is conventionally defined as a naturally occurring substance — originating from plant, animal, or mineral sources — that has undergone no chemical modification beyond primary collection and drying. These materials serve as the foundational substrates for the manufacture of herbal medicines, phytopharmaceuticals, galenical preparations, and the isolation of bioactive lead compounds. Familiar examples encompass dried *Senna* leaves, *Cinchona* bark, dried *Rauwolfia serpentina* roots, opium latex, and mineral products such as kaolin. Traditional medicine systems — including Ayurveda, Unani, Siddha, and Traditional Chinese Medicine — have codified the therapeutic application of crude drugs over millennia, and these substances continue to underpin modern drug discovery pipelines. Prominent pharmaceuticals including morphine, quinine, vincristine, paclitaxel, and artemisinin are either directly plant-derived or structurally modelled upon natural lead compounds [1,2].

1.2 The Problem of Compositional Variability

Unlike synthetic pharmaceuticals — whose molecular identity, purity, and pharmacokinetic characteristics are tightly controlled by manufacturing protocols — crude drugs represent complex biological matrices subject to substantial compositional variation. The concentration of therapeutically active secondary metabolites in any given batch may differ by orders of magnitude from another batch, directly influencing both therapeutic potency and toxicological safety. Principal sources of such variability include:

1.3 The Imperative of Quality Control and Standardization

Quality control, in the pharmaceutical context, denotes the totality of procedures undertaken to verify the identity, purity, potency, and safety of a product prior to its release for clinical or commercial use. For crude drugs, this encompasses an integrated battery of analytical tests spanning sensory evaluation through sophisticated mass spectrometric analysis. Standardization goes a step further, seeking to adjust the concentration of therapeutically relevant constituents — by blending batches or incorporating excipients — to achieve a reproducible, predefined specification that ensures consistent therapeutic outcomes across product lots [3]. The principal objectives of crude drug quality control are multifaceted:

- To confirm species identity and guard against substitution with morphologically similar but chemically distinct taxa.
- To quantify the content of active principles or chemically defined marker compounds and ensure adequacy for therapeutic effect.
- To detect and limit toxic contaminants including heavy metals, organochlorine and organophosphorus pesticide residues, aflatoxins, and pathogenic microorganisms.
- To enforce batch-to-batch reproducibility, underpinning consistent clinical performance.

- To satisfy the regulatory requirements of national pharmacopoeias and international bodies such as the World Health Organization (WHO) [1,3].

II. DRUG PROFILES: CASE STUDY DRUGS

2.1 Neem (Azadirachta indica A.Juss.)

Attribute	Details
Synonyms	Indian Lilac; Margosa Tree; Nimtree; Persian Lilac
Biological Source	Dried leaves and bark of Azadirachta indica A.Juss.
Family	Meliaceae
Geographical Source	Indigenous to the Indian subcontinent; widely cultivated throughout tropical Asia and Africa
Principal Constituents	Azadirachtin (tetranortriterpenoid limonoid), nimbin, nimbidin, nimbidol, gedunin, quercetin, kaempferol
Therapeutic Uses	Antimicrobial, antifungal, insecticidal, anti-inflammatory, immunomodulatory, hypoglycaemic

Table 1. Botanical and pharmacological profile of Neem (A. indica)

2.2 Turmeric (Curcuma longa L.)

Attribute	Details
Synonyms	Haldi; Indian Saffron; Curcuma; Jiang Huang (TCM)
Biological Source	Dried rhizomes of Curcuma longa L.
Family	Zingiberaceae
Geographical Source	Native to South Asia; major commercial cultivation in India (Andhra Pradesh, Tamil Nadu, Odisha), China, and Indonesia
Principal Constituents	Curcumin (curcuminoid I), demethoxycurcumin, bisdemethoxycurcumin; volatile oil (turmerone, ar-turmerone, zingiberene)
Therapeutic Uses	Anti-inflammatory (COX-2 inhibition), antioxidant, hepatoprotective, antineoplastic (adjunct), wound-healing

Table 2. Botanical and pharmacological profile of Turmeric (C. longa)

III. ORGANOLEPTIC AND MACROSCOPIC EVALUATION

Organoleptic evaluation — sometimes referred to synonymously as macroscopic or morphological evaluation — employs the trained human senses of sight, smell, taste, and touch to derive a

preliminary characterization of a crude drug's identity and quality. While inherently subjective and incapable of yielding quantitative data, organoleptic assessment serves as a rapid, cost-effective first-line screening tool that can flag gross adulteration, substitution, improper drying, or microbial spoilage well before laboratory analyses are initiated [4,5].

3.1 Key Organoleptic Parameters

Table 3. Comparative organoleptic characteristics of Neem and Turmeric

Parameter	Neem (A. indica)	Turmeric (C. longa)
Colour	Vivid green to dark olive-green	Deep yellow to orange-yellow
Odour	Characteristic pungent-bitter odour	Characteristic warm aromatic odour
Taste	Intensely bitter	Bitter and mildly pungent
Shape	Lanceolate leaflets; serrated margin; pointed apex	Cylindrical, finger-like branched rhizomes
Surface Texture	Glabrous to slightly rough; serrated margins	Wrinkled brownish-yellow outer surface
Fracture Type	Short fracture	Horny, waxy fracture
Internal Colour	Pale yellowish-green	Deep bright orange

IV. MICROSCOPIC EVALUATION

When a crude drug has been reduced to a powder — as is the case with the majority of herbal raw materials entering pharmaceutical manufacturing — macroscopic features are largely obliterated, rendering microscopic analysis indispensable. Microscopical examination identifies characteristic cellular elements — specific cell types, tissue arrangements, and non-living ergastic inclusions — that constitute diagnostic 'fingerprints' enabling unequivocal species confirmation and adulteration detection [6,7].

4.1 Sample Preparation Approaches

4.2 Diagnostic Cellular Elements

4.2.1 Vascular and Mechanical Tissues

Xylem vessels exhibit characteristic secondary wall thickening patterns (annular, helical, scalariform, reticulate, and bordered pit types) that are highly taxon-specific. Sclerenchymatous elements — including thick-walled, lignified fibres and variously-shaped sclereids (stone cells) — provide additional diagnostic markers detectable by their positive phloroglucinol-HCl staining reaction.

4.2.2 Ergasti
c Inclusions

4.2.3 Epidermal Features: Trichomes and Stomata
Trichomes are classified as covering (non-glandular; protective function) or glandular (secretory; volatile oil reservoir). The stomatal type — defined by the arrangement of subsidiary cells relative to guard cells — constitutes one of the most reliably constant microscopic characters. Principal types encountered in pharmacognostic practice include:

4.3 Quantitative Microscopic Constants
Numerical leaf constants provide objective, reproducible parameters for differentiating closely related species and detecting admixture. Principal constants include:

Table 4. Comparative diagnostic microscopic characters of Neem and Turmeric

Microscopic Character	Neem (A. indica)	Turmeric (C. longa)
Epidermis	Single-layered, cuticularized epidermis	Cork cells present in outer cortical zone
Stomatal Type	Anomocytic; present on both leaf surfaces	Absent (rhizome tissue)
Trichomes	Simple multicellular covering trichomes	Absent in rhizome
Calcium Oxalate	Present (prismatic/rosette types)	Rare to absent
Starch Grains	Sparse, simple grains	Abundant; simple and compound grains
Oleoresin Cells	Occasionally present	Abundant; impart yellow colouration
Xylem Vessels	Spiral and pitted types	Reticulate and spiral types
Key Diagnostic Feature	Calcium oxalate crystals and multicellular trichomes	Yellow oleoresin cells + abundant starch grains

V. PHYSICAL EVALUATION

Physicochemical determinations yield objective, quantitative data that are enshrined in pharmacopoeial monographs and provide a primary line of defense against adulteration and degradation. The following parameters are routinely performed and cross-referenced against official pharmacopoeial limits [8,9].

5.1 Moisture Content (Loss on Drying, LOD)
Residual moisture above the pharmacopoeially specified threshold promotes enzymatic degradation of labile active constituents, facilitates colonization by mould and bacteria, and

accelerates hydrolysis of sensitive glycosides. The Loss on Drying method determines total volatile matter (water and low-boiling volatiles) lost from a 2–5 g sample dried in a thermostatically controlled oven at 105°C (or at reduced temperature under vacuum for thermolabile drugs) to constant mass.
Formula: LOD (%) = [(Initial mass − Dried mass) / Initial mass] × 100

5.2 Ash Value Determinations
Upon complete incineration at 450 ± 25°C, all organic matter is oxidized, leaving an inorganic residue whose composition reflects both the plant's endogenous mineral content (physiological ash) and exogenous contamination from adhering soil, sand, and dust (non-physiological ash). Three principal ash tests are recognized [8,9]:

Table 5. Pharmacopoeial ash value limits for Neem and Turmeric (IP specifications)

Ash Value Parameter	Neem (A. indica)	Turmeric (C. longa)
Total Ash	NMT 16% w/w	NMT 9% w/w
Acid-Insoluble Ash	NMT 2% w/w	NMT 1% w/w
Water-Soluble Ash	NLT 3% w/w	NLT 1.5% w/w
Sulphated Ash	~17% w/w	~10% w/w

NMT = Not More Than; NLT = Not Less Than

5.3 Extractive Values
The solvent-extractable fraction provides an indirect measure of soluble bioactive constituent load. Three principal extractive solvents are employed, chosen to selectively partition different chemical classes [8,9]:

Table 6. Pharmacopoeial extractive value limits for Neem and Turmeric (IP specifications)

Extractive Value	Neem (A. indica)	Turmeric (C. longa)
Alcohol-Soluble Extractive	NLT 10% w/w	NLT 8% w/w
Water-Soluble Extractive	NLT 15% w/w	NLT 12% w/w
Ether-Soluble Extractive	NLT 2% w/w	NLT 5% w/w

5.4 Additional Physical Constants

VI. CHEMICAL EVALUATION

6.1 Preliminary Qualitative Phytochemical Screening
A systematic battery of colourimetric precipitation reactions is performed on sequentially prepared extracts (petroleum ether → chloroform → ethanol → water) to establish the presence or absence

of major secondary metabolite classes. This screening directs subsequent targeted analytical investigations [10,11].

Table 7. Principal qualitative chemical tests for common secondary metabolite classes

Phytochemical Class	Test Name and Reagent	Positive Result
Alkaloids	Dragendorff's Test (potassium bismuth iodide)	Orange-brown precipitate
Alkaloids	Mayer's Test (potassium mercuric iodide)	Cream precipitate
Cardiac Glycosides	Keller-Kiliani Test ($FeCl_3$ + glacial AcOH + conc. H_2SO_4)	Reddish-brown ring; upper blue-green
Anthraquinones	Borntrager's Test (dil. H_2SO_4; NH_3 shake)	Pink-to-cherry-red ammoniacal layer
Flavonoids	Shinoda Test (Mg ribbon + conc. HCl)	Pink/crimson/magenta colouration
Tannins	Ferric Chloride Test (5% $FeCl_3$)	Blue-black or greenish-black colour
Saponins	Foam Test (vigorous aqueous shaking)	Persistent honeycomb froth ≥ 2 min
Steroids/Triterpenoids	Liebermann-Burchard Test (AcO_2 + conc. H_2SO_4)	Blue-green (steroids); pink-red (triterpenoids)
Carbohydrates	Molisch's Test (α-naphthol + conc. H_2SO_4)	Purple-violet ring at interface
Curcuminoids (Turmeric)	Boric Acid Test (boric acid + oxalic acid)	Reddish-brown colouration (rosocyanin)

6.2 Chromatographic Methods

6.2.1 Thin-Layer Chromatography (TLC)

TLC affords rapid, cost-effective comparison of constituent profiles between test samples and authenticated reference materials. Characteristic Rf values and colour reactions under UV (254 nm, 366 nm) and after derivatization with universal detection reagents (vanillin-sulphuric acid, anisaldehyde-sulphuric acid) provide reliable identity confirmation.

6.2.2 High-Performance Thin-Layer Chromatography (HPTLC)

HPTLC, employing densitometric scanning with diode-array detection, substantially extends TLC to semi-quantitative fingerprint profiling. Simultaneous chromatographic fingerprints from

multiple samples, when processed by chemometric algorithms (Principal Component Analysis, Hierarchical Cluster Analysis), facilitate authentication and geographic origin discrimination [11].

6.2.3 High-Performance Liquid Chromatography (HPLC)

Reversed-phase HPLC with UV-DAD or mass spectrometric detection remains the gold-standard method for quantification of marker compounds in crude drugs. Standard methods include IP/BP/USP assays for curcuminoids in Turmeric (C18 column, acetonitrile-phosphate buffer gradient, detection at 420 nm) and azadirachtin in Neem (C18, water-acetonitrile, detection at 215 nm) [11].

6.2.4 Gas Chromatography–Mass Spectrometry (GC-MS)

GC-MS is the method of choice for volatile oil constituent profiling. Compounds are identified by matching mass spectral fragmentation patterns against library databases (NIST, Wiley) and by comparison of calculated Kovats retention indices with published reference values.

6.3 Spectroscopic Methods

UV-visible spectrophotometry provides rapid, accessible quantification for chromophoric constituents (e.g., total curcuminoids at 425 nm). Infrared (FTIR) spectroscopy generates characteristic absorption fingerprints of functional groups, enabling rapid discrimination between genuine drugs and adulterants. Nuclear magnetic resonance (NMR) spectroscopy — though requiring substantial infrastructure — delivers unambiguous structural characterization of isolated constituents and is the definitive tool for discovering novel adulterants [11,12].

Table 8. Major phytochemical constituents and corresponding chemical identification tests for Neem and Turmeric

Constituent Class	Neem (A. indica)	Turmeric (C. longa)
Key Marker Compounds	Azadirachtin, nimbin, nimbidin, nimbidol, gedunin, quercetin	Curcumin, demethoxycurcumin, bisdemethoxycurcumin, turmerone
Alkaloid Test	Dragendorff's Test: positive (orange-brown ppt.)	Dragendorff's Test: negative
Tannin Test	Ferric Chloride: positive (blue-black)	Ferric Chloride: weakly positive
Flavonoid Test	Shinoda Test: positive (magenta)	Shinoda Test: positive
Curcuminoid Test	Not applicable	Boric Acid Test: reddish-brown (rosocyanin)
Chromatographic Marker	Azadirachtin (HPLC, 215 nm)	Curcumin (HPLC, 425 nm; TLC Rf ≈ 0.51 in toluene-EtOAc 93:7)

VII. BIOLOGICAL EVALUATION AND CONTAMINANT TESTING

Safety verification is equally as critical as efficacy confirmation in crude drug quality control. Comprehensive safety assessment encompasses testing for heavy metal accumulation, residual agrochemical contamination, mycotoxin presence, and microbiological burden — all of which carry direct public health implications [13,14].

7.1 Heavy Metal Analysis

Medicinal plants cultivated on metal-contaminated soils or irrigated with polluted water may bioaccumulate toxic trace elements. Chronic human exposure to lead, cadmium, mercury, and arsenic — even at sub-threshold doses — produces cumulative neurotoxic, nephrotoxic, and carcinogenic effects. The WHO has established upper permissible limits for these elements in herbal drugs [13].

Table 9. WHO-recommended upper permissible limits for heavy metals in herbal drugs

Heavy Metal	Permissible Limit (µg/g dry weight)	Analytical Method
Lead (Pb)	≤ 10.0	GFAAS / ICP-MS
Cadmium (Cd)	≤ 0.3	GFAAS / ICP-MS
Mercury (Hg)	≤ 1.0	CV-AAS / ICP-MS
Arsenic (As)	≤ 5.0	HG-AAS / ICP-MS

GFAAS = Graphite Furnace Atomic Absorption Spectroscopy; CV-AAS = Cold-Vapour AAS; HG-AAS = Hydride Generation AAS; ICP-MS = Inductively Coupled Plasma Mass Spectrometry.

7.2 Pesticide Residue Analysis

Organochlorine, organophosphorus, carbamate, and pyrethroid pesticide residues in herbal materials are quantified by GC with selective detectors (Electron Capture Detector for organochlorines; Flame Photometric Detector for organophosphorus) or by LC-MS/MS for polar and non-volatile residues. Both WHO and major pharmacopoeias specify maximum residue limits (MRLs) for individual pesticide classes, with GC-MS used as a confirmatory technique [13].

7.3 Mycotoxin Screening

Aflatoxins (B1, B2, G1, G2) — hepatocarcinogenic polyketide metabolites elaborated principally by Aspergillus flavus and A. parasiticus — may accumulate in crude drugs stored under inadequate temperature and humidity controls. WHO specifies that aflatoxin B1 must not exceed 5 µg/kg, and total aflatoxins (B1 + B2 + G1 + G2) must not surpass 10 µg/kg in herbal drugs. Detection and quantification are achieved by immunoaffinity column cleanup followed by HPLC with fluorescence detection (post-column photochemical derivatization) or by LC-MS/MS [13,14].

7.4 Microbiological Quality

Crude drugs, particularly those with high polysaccharide and reducing sugar content, are susceptible to contamination by yeasts, moulds, and potentially pathogenic bacteria during collection, processing, and storage. Pharmacopoeial microbial quality testing quantifies total aerobic microbial count (TAMC), total yeast and mould count (TYMC), and screens for specified indicator organisms [14].

Table 10. WHO and pharmacopoeial microbiological acceptance criteria for herbal drugs

Microbiological Parameter	Acceptance Limit	Analytical Approach
Total Aerobic Microbial Count	≤ 10^5 CFU/g	Plate count / membrane filtration
Total Yeast & Mould Count	≤ 10^3 CFU/g	Culture on selective media
Escherichia coli	Absent per 1 g	MacConkey broth; IMViC tests
Salmonella spp.	Absent per 25 g	Selenite broth; XLD agar
Pseudomonas aeruginosa	Absent per 1 g	Cetrimide agar; oxidase test
Staphylococcus aureus	Absent per 1 g	Mannitol salt agar; coagulase test

7.5 Pharmacological Bioassays

When chemical quantification is inappropriate — either because the active principle is unknown or because the biological response cannot be adequately predicted from constituent concentration — bioassays are applied. The classic Digitalis Leaf potency assay (cardiac arrest in anaesthetized guinea pig or pigeon; result expressed as International Units per gram) exemplifies this approach. Contemporary in-vitro bioassays include enzyme-inhibition assays (e.g., α-glucosidase inhibition for antidiabetic crude drugs), receptor-binding assays, and cytotoxicity profiling in cell-line models [14].

VIII. ADULTERATION: TYPES, DETECTION AND REGULATORY RESPONSE

Adulteration — the deliberate or inadvertent degradation of crude drug quality through admixture of inferior, foreign, or exhausted material — remains a serious challenge to the integrity of the global herbal medicines supply chain. Principal categories recognized in pharmacognostic practice include [5,15]:

IX. EMERGING ANALYTICAL APPROACHES IN CRUDE DRUG QUALITY CONTROL

9.1 Chromatographic Fingerprinting and Chemometrics

Holistic quality assessment through fingerprint profiling has superseded single-marker assays as the preferred paradigm for crude drug standardization. HPTLC and HPLC chromatograms generate complex multi-peak patterns representative of the entire extractable phytochemical

composition. When subjected to multivariate statistical processing — Principal Component Analysis (PCA) for dimensionality reduction, Partial Least Squares Discriminant Analysis (PLS-DA) for classification, and hierarchical clustering for dendrogram visualization — these fingerprints enable discrimination of species, geographical origins, harvest seasons, and adulterated lots with high classification accuracy [11,15].

9.2 DNA Barcoding and Molecular Authentication

Short, standardized genomic regions — designated as barcodes — permit definitive species identification at the molecular level, irrespective of the physical form of the material (whole, powdered, or processed). The core plant barcode regions ITS2, matK, and rbcL are internationally endorsed and successfully distinguish closely related congeners that are morphologically indistinguishable in powdered form. Next-generation sequencing (NGS)-based metabarcoding is extending this approach to detect complex multi-species adulterant mixtures simultaneously [15].

9.3 Metabolomics

Untargeted metabolomic profiling — conducted by high-resolution LCMS or by ^{1}H-NMR spectroscopy — generates comprehensive chemical fingerprints encompassing hundreds to thousands of metabolites simultaneously. Integrated with chemometric analysis, metabolomics facilitates discovery of species-specific biomarkers, assessment of environmental influence on metabolite profiles, and early-stage detection of subtle adulteration that evades targeted single-constituent assays [15].

9.4 Portable Near-Infrared (NIR) Spectroscopy

Miniaturized NIR spectrometers coupled with pre-trained chemometric models now enable non-destructive, rapid, on-site identity verification of crude drugs without sample preparation — a transformative development for supply-chain surveillance in resource-limited settings and at points of importation.

10. REGULATORY AND PHARMACOPOEIAL FRAMEWORK

The establishment and enforcement of quality standards for crude drugs is embedded within an interconnected hierarchy of national pharmacopoeias and international guidelines [1,2,3]:

Table 11. Major pharmacopoeias providing quality standards for crude drugs and herbal preparations

Pharmacopoeia	Abbrev.	Publishing Body	Scope and Relevance
Indian Pharmacopoeia	IP	Indian Pharmacopoeia Commission, MoHFW	Official compendium for drugs manufactured in India; extensive herbal monographs
Ayurvedic Pharmacopoeia of India	API	Ministry of AYUSH, Govt. of India	Standards for single Ayurvedic crude drugs and formulations

Pharmacopoeia	Abbrev.	Publishing Body	Scope and Relevance
British Pharmacopoeia	BP	British Pharmacopoeia Commission	UK and Commonwealth reference; harmonized herbal monographs
United States Pharmacopeia	USP	USP Convention	US reference; extensive botanical extract monographs
European Pharmacopoeia	Ph.Eur.	EDQM, Council of Europe	Legally binding in EU; harmonized herbal drug and preparation standards
WHO Guidelines	—	World Health Organization	Global framework for GACP, quality control methods, contaminant limits

The WHO has been particularly instrumental in harmonizing global quality standards, publishing key reference texts: Quality Control Methods for Medicinal Plant Materials (1998; updated 2011), WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants (2003), and Guidelines for Assessing Quality of Herbal Medicines with Reference to Contaminants and Residues (2007). Together, these documents provide a unified technical and regulatory roadmap spanning the entire crude drug supply chain from cultivation through laboratory release testing [1,2,3].

XI. CONCLUSIONS AND FUTURE PERSPECTIVES

The quality control of crude drugs is a scientifically rigorous, multidimensional discipline that cannot be reduced to any single test or analytical category. As demonstrated in this review — with Neem and Turmeric serving as illustrative case studies — ensuring the safety, efficacy, and identity of a herbal drug demands the seamless integration of organoleptic, microscopical, physicochemical, chemical, and biological data streams, each interrogating different dimensions of quality from macroscopic to molecular scales.

A pivotal insight from this analysis is that no single parameter provides sufficient assurance in isolation. Chromatographic fingerprinting without microscopical identity confirmation leaves the door open for species substitution; ash value determination without extractive value assessment may miss exhausted drug admixtures; heavy metal testing without pesticide residue screening provides incomplete safety assurance. Only a holistic, integrated approach — anchored in internationally harmonized pharmacopoeial standards and WHO guidance — can deliver the level of quality assurance demanded by modern regulatory environments and patient safety obligations.

Several exciting frontiers are reshaping crude drug quality assurance. The progressive integration of DNA barcoding and NGS metabarcoding into routine quality workflows promises to virtually eliminate botanical misidentification and undeclared species substitution. Metabolomic profiling combined with AI-driven chemometric classifiers is transitioning from specialized research tools toward practical quality management instruments. Portable NIR spectrometers equipped with pre-trained classification models offer the prospect of real-time, non-destructive quality gatekeeping

at the point of supply-chain entry. Finally, the global harmonization of pharmacopoeial standards — facilitated by multilateral collaborations between IP, USP, Ph.Eur., and WHO — is progressively reducing the regulatory disparity that has historically allowed substandard herbal products to enter international trade.

By embracing these scientific and regulatory advances while preserving the analytical rigor established by generations of pharmacognostic scholarship, the herbal medicines sector can fulfill its promise of delivering reproducibly safe, efficacious, and authentic therapeutic products to the global population that depends upon them.

DECLARATIONS

Conflict of Interest

The authors declare that no conflict of interest, financial or otherwise, exists in relation to the subject matter or materials discussed in this manuscript.

Funding

No external funding was received for the preparation of this review article.

Ethical Approval

This review article does not involve any human participants or animal experimentation; hence formal ethical committee approval is not applicable.

REFERENCES

[1] World Health Organization. Quality Control Methods for Medicinal Plant Materials. WHO Press, Geneva, 1998; updated 2011.

[2] World Health Organization. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. WHO Press, Geneva, 2003.

[3] Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. IPC, Ghaziabad, 2022.

[4] Evans WC. Trease and Evans Pharmacognosy. 16th ed. Saunders Elsevier, London, 2011.

[5] Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 48th ed. Nirali Prakashan, Pune, 2014.

[6] Khandelwal KR. Practical Pharmacognosy: Techniques and Experiments. 23rd ed. Nirali Prakashan, Pune, 2013.

[7] Ahmed A, Hasan M. Microscopic evaluation as a tool for pharmacognostic authentication of crude drugs: A systematic review. Asian Pacific Journal of Tropical Biomedicine. 2024;14(2):45–58.

[8] Balekundri A, Mannur V. Quality control of the traditional medicines: challenges and perspectives. Future Journal of Pharmaceutical Sciences. 2020;6(1):67.

[9] Wallis TE. Textbook of Pharmacognosy. 5th ed. CBS Publishers, New Delhi, 2005.

[10] Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. Chapman & Hall, London, 1998.

[11] Devi A, et al. Recent advances in analytical techniques for quality control of herbal drugs: an integrative review. Journal of Ethnopharmacology. 2025;320:117943.

[12] Wei F, et al. Spectroscopic methods and their application in quality control of plant-derived drugs. Phytochemical Analysis. 2020;31(4):421–440.
[13] Kumar V, et al. Heavy metal contamination in medicinal plants: sources, toxicity and regulatory frameworks. Environmental Science and Pollution Research. 2022;29(18):26543–26562.
[14] Edo GI, et al. Microbiological and mycotoxin contamination of herbal medicines: a decade of evidence (2013–2024). Food and Chemical Toxicology. 2024;185:114532.
[15] Mukherjee PK. Quality Control of Herbal Drugs: An Approach to Evaluation of Botanicals. 2nd ed. Business Horizons, New Delhi, 2019.